Pharmaceutical Investing Auris Medical Receives Positive Scientific Advice from EMA on Development Plan and Regulatory Pathway for AM-111
Eloxx Pharmaceuticals Announces FDA Grant of Orphan-Drug Designation for Investigational Drug ELX-02 for Treatment of Cystinosis
Pharmaceutical Investing Trillium Therapeutics’ TTI-621 Receives Orphan Drug Designation for the Treatment of Cutaneous T-Cell Lymphoma
Pharmaceutical Investing Abeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 Disease
Pharmaceutical Investing Ovid Therapeutics Announces OV101 Granted Fast Track Designation by U.S. FDA for Treatment of Fragile X Syndrome
Pharmaceutical Investing Proteostasis Therapeutics Announces FDA Grants Orphan Drug Designation for PTI-428 in Cystic Fibrosis
Pharmaceutical Investing Midatech receives Orphan Drug Designation for MTD119 from the European Medicines Agency
Pharmaceutical Investing ContraVir Pharmaceuticals Announces TXL Has Been Granted Orphan Drug Designation for the Treatment of HBV in a Pediatric Population
U.S. FDA Files New Drug Application Under Priority Review for Migalastat for Treatment of Fabry Disease
Strongbridge Biopharma Announces Acquisition of the U.S. and Canadian Rights to MACRILEN™ (macimorelin) from Aeterna Zentaris
Strongbridge Biopharma Receives Notice of Allowance from U.S. Patent and Trademark Office for New Patent
Cartier Resources Closes Offering with Paradigm Capital and Concurrent Offering for Aggregate Gross Proceeds of $11,398,596
